HC Wainwright Has Bullish Estimate for Insmed Q3 Earnings

Insmed, Inc. (NASDAQ:INSM) – Equities research analysts at HC Wainwright lifted their Q3 2026 earnings per share estimates for Insmed in a research report issued on Monday, August 10th. HC Wainwright analyst A. Fein now expects that the biopharmaceutical company will post earnings per share of ($0.31) for the quarter, up from their prior estimate of ($0.82). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Insmed’s current full-year earnings is ($2.00) per share. HC Wainwright also issued estimates for Insmed’s Q4 2026 earnings at ($0.49) EPS, FY2027 earnings at $1.62 EPS, FY2028 earnings at $3.38 EPS and FY2030 earnings at $10.92 EPS.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%.The business had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same quarter in the previous year, the firm earned ($1.70) earnings per share. The business’s revenue was up 296.1% on a year-over-year basis.

INSM has been the subject of a number of other research reports. JPMorgan Chase & Co. decreased their price objective on shares of Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday. Jefferies Financial Group reiterated a “buy” rating and issued a $175.00 target price on shares of Insmed in a research note on Thursday, August 6th. Cantor Fitzgerald reissued an “overweight” rating and set a $235.00 target price on shares of Insmed in a research report on Tuesday, July 28th. Wells Fargo & Company raised their price target on shares of Insmed from $161.00 to $169.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $218.00 price target on shares of Insmed in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $205.52.

Insmed Trading Down 1.6%

NASDAQ INSM opened at $132.57 on Wednesday. The business’s fifty day moving average is $106.29 and its 200-day moving average is $128.64. The company has a debt-to-equity ratio of 0.74, a current ratio of 3.72 and a quick ratio of 3.40. The stock has a market capitalization of $28.95 billion, a price-to-earnings ratio of -32.26 and a beta of 0.81. Insmed has a one year low of $90.39 and a one year high of $212.75.

Institutional Investors Weigh In On Insmed

Large investors have recently added to or reduced their stakes in the business. CIBC Private Wealth Group LLC lifted its holdings in Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. EverSource Wealth Advisors LLC grew its position in shares of Insmed by 10.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after buying an additional 69 shares during the last quarter. Private Advisor Group LLC increased its stake in shares of Insmed by 1.8% during the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock valued at $777,000 after buying an additional 82 shares during the period. Glenmede Trust Co. NA increased its stake in shares of Insmed by 5.4% during the first quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock valued at $313,000 after buying an additional 98 shares during the period. Finally, Allworth Financial LP raised its holdings in shares of Insmed by 20.5% during the fourth quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 108 shares in the last quarter.

Insider Buying and Selling at Insmed

In other Insmed news, CEO William Lewis sold 21,398 shares of Insmed stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $103.32, for a total transaction of $2,210,841.36. Following the completion of the transaction, the chief executive officer owned 258,917 shares of the company’s stock, valued at $26,751,304.44. The trade was a 7.63% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 6,149 shares of the business’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $108.47, for a total transaction of $666,982.03. Following the transaction, the insider directly owned 41,613 shares of the company’s stock, valued at approximately $4,513,762.11. This represents a 12.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 54,590 shares of company stock worth $5,793,738 over the last ninety days. Company insiders own 2.10% of the company’s stock.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.